Background: Facial nerve schwannomas account for about 0.8% of all petrous mass lesions. Schwannomas of the greater superficial petrosal nerve (GSPN) are a rare subtype with few case-reports up to date.

Case Presentations: A retrospective analysis of clinical outcomes, radiographic findings and postoperative complication between June 2007 and December 2020 was performed. Four cases of GSPN schwannomas were reported. The presenting symptoms were facial nerve palsy and hearing loss. Imaging studies showed a subtemporal mass on the anterosuperior aspect of the petrous bone, in one case with extraordinary petrous bone and mastoid infiltration and destruction. Three cases were removed through a subtemporal extra- or intradural approach, one case via a combined pre- and retrosigmoid approach. Improvement of facial nerve palsy occurred in one case; new hearing loss was observed in another case. Xeropthalmia was a short-term temporary deficit in three cases. Short- to mid-term follow-up of the patients has not shown any tumor recurrence.

Conclusions: GSPN schwannomas are rare entities presenting with heterogenous symptoms. Our surgical findings emphasize safe resection. Complete remission is possible by GTR. Since the small data set limits the expressiveness of statements regarding standard of care and alternative therapy options, additional data is needed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733176PMC
http://dx.doi.org/10.1186/s12883-022-02960-3DOI Listing

Publication Analysis

Top Keywords

facial nerve
12
schwannomas greater
8
greater superficial
8
superficial petrosal
8
petrosal nerve
8
gspn schwannomas
8
nerve palsy
8
hearing loss
8
petrous bone
8
three cases
8

Similar Publications

Granulocyte colony-stimulating factor promotes regeneration of severed facial nerve in rats.

Front Neurosci

December 2024

Department of Otorhinolaryngology and Head and Neck Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Background And Aim: The administration of growth and neurotrophic factors has been attempted experimentally as a new therapeutic strategy for severe facial paralysis. Granulocyte colony-stimulating factor (G-CSF) has an effect on the treatment of central nervous system injuries, such as cerebral infarction and spinal cord injury. This study aimed at examining the effects of G-CSF on facial nerve regeneration in rats.

View Article and Find Full Text PDF

Application of neurophysiological monitoring in differentiation of hemifacial spasm and post-facial paralysis synkinesis.

Neurophysiol Clin

December 2024

Department of Neurosurgery, Xinhua Hospital, Shanghai Jiaotong University, School of Medicine, The Cranial Nerve Disease Center of Shanghai Jiaotong University, 1665 Kongjiang Road, Shanghai 200092, China. Electronic address:

Objective: The aims of this study were to investigate the electrophysiological features of hemifacial spasm (HFS) and post-facial paralysis synkinesis (PFPS) that contribute to differential diagnosis.

Methods: This study was designed as a retrospective analysis, focusing on 132 patients diagnosed with HFS and 78 patients with PFPS between May and October 2023. Patient data were collected from existing medical records.

View Article and Find Full Text PDF

Selective midfacial neurectomy for postparalytic facial nerve syndrome.

J Plast Reconstr Aesthet Surg

November 2024

Department of Plastic and Reconstructive Surgery, Ichikawa General Hospital, Tokyo Dental College, Ichikawa, Japan.

Chemodenervation with botulinum A toxin and neuromuscular retraining therapy are commonly performed as first-line treatments for postparalytic facial nerve syndrome (PFS). However, their effects are temporary, and side effects typically develop. Currently available selective neurectomy approaches are limited by variations in the anatomy of the peripheral branches of the facial nerve and the ability to reduce perioral synkinesis, but not periocular synkinesis.

View Article and Find Full Text PDF

You-Hoover-Fong syndrome (YHFS) is a rare autosomal recessive disorder characterized by global developmental delay, microcephaly, dysmorphic facial features, and a spectrum of neurodevelopmental abnormalities. YHFS is caused by pathogenic variants in TELO2, a gene involved in regulation of the cell cycle. To date, 29 individuals with YHFS have been reported and none of them has been reported to develop tumors.

View Article and Find Full Text PDF

Objective: Multiple techniques have been used to treat trigeminal neuralgia (TGN), including pharmacotherapy, radiosurgery, rhizotomy and microvascular decompression (MVD). Blood vessels are considered to be the most common cause of offense and compression to trigeminal nerve. We aimed to determine the causes of classic TGN and efficacy of MVD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!